Polymyalgia rheumatica natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Polymyalgia rheumatica (PMR) affects the quality of life of the patients. The pain and stiffness in the proximal joints might lead to sleep disturbance as well as inability to do regular daily activities such as getting dressed and getting out of a chair. The symptoms begin rapidly and last for weeks. Once the [[steroid]] treatment of PMR is initiated, the symptoms resolve rapidly within few days. In fact, the rapid resolution of symptoms with the [[steroid]] therapy reinforces the diagnosis of PMR. The [[steroid]] treatment can be associated with complicationssuch as [[weight gain]] and bone fracture.<ref name="pmid23051717">{{cite journal| author=Kermani TA, Warrington KJ| title=Polymyalgia rheumatica. | journal=Lancet | year= 2013 | volume= 381 | issue= 9860 | pages= 63-72 | pmid=23051717 | doi=10.1016/S0140-6736(12)60680-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23051717 }} </ref> Approximately 40 to 50% of subjects experience relapse of the symptoms. PMR is associated with [[giant cell arteritis]]. | |||
==Natural History== | ==Natural History== | ||
If left untreated, PMR affects the quality of life of the patients. The pain and stiffness in the proximal joints might lead to sleep disturbance as well as inability to do regular daily activities such as getting dressed and getting out of a chair. The symptoms begin rapidly and last for weeks. | * If left untreated, PMR affects the quality of life of the patients. The pain and stiffness in the proximal joints might lead to sleep disturbance as well as inability to do regular daily activities such as getting dressed and getting out of a chair. The symptoms begin rapidly and last for weeks. | ||
==Complications== | ==Complications== | ||
* PMR is associated with [[giant cell arteritis]]. While 40 to 60% of patients with [[giant cell arteritis]] have PMR, 16 to 21% of patients with PMR develop [[giant cell arteritis]].<ref name="pmid7598301">{{cite journal| author=Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG| title=The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. | journal=Ann Intern Med | year= 1995 | volume= 123 | issue= 3 | pages= 192-4 | pmid=7598301 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7598301 }} </ref><ref name="pmid7880191">{{cite journal| author=Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG| title=Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. | journal=Arthritis Rheum | year= 1995 | volume= 38 | issue= 3 | pages= 369-73 | pmid=7880191 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7880191 }} </ref><ref name="pmid1629827">{{cite journal| author=Franzén P, Sutinen S, von Knorring J| title=Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. | journal=J Rheumatol | year= 1992 | volume= 19 | issue= 2 | pages= 273-6 | pmid=1629827 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1629827 }} </ref> Some symptoms of [[temporal arteritis]] include severe [[headaches]], scalp tenderness, [[jaw claudication]], [[fever]], distorted vision or aching in the limbs caused by decreased blood flow, and [[fatigue]]. [[Giant cell arteritis]] is a serious condition that might lead to blindness among other complications and it must be treated with high dose [[ | * PMR is associated with [[giant cell arteritis]]. While 40 to 60% of patients with [[giant cell arteritis]] have PMR, 16 to 21% of patients with PMR develop [[giant cell arteritis]].<ref name="pmid7598301">{{cite journal| author=Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG| title=The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. | journal=Ann Intern Med | year= 1995 | volume= 123 | issue= 3 | pages= 192-4 | pmid=7598301 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7598301 }} </ref><ref name="pmid7880191">{{cite journal| author=Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG| title=Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. | journal=Arthritis Rheum | year= 1995 | volume= 38 | issue= 3 | pages= 369-73 | pmid=7880191 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7880191 }} </ref><ref name="pmid1629827">{{cite journal| author=Franzén P, Sutinen S, von Knorring J| title=Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. | journal=J Rheumatol | year= 1992 | volume= 19 | issue= 2 | pages= 273-6 | pmid=1629827 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1629827 }} </ref> Some symptoms of [[temporal arteritis]] include severe [[headaches]], scalp tenderness, [[jaw claudication]], [[fever]], distorted vision or aching in the limbs caused by decreased blood flow, and [[fatigue]]. [[Giant cell arteritis]] is a serious condition that might lead to blindness among other complications and it must be treated with high dose [[corticosteroids]]. | ||
* The mainstay of the treatment of PMR is low dose [[ | * The mainstay of the treatment of PMR is low dose [[corticosteroids]], which is byitself associated with complications. Complications of the [[steroid]] treatment include [[weight gain]] and bone fracture.<ref name="pmid23051717">{{cite journal| author=Kermani TA, Warrington KJ| title=Polymyalgia rheumatica. | journal=Lancet | year= 2013 | volume= 381 | issue= 9860 | pages= 63-72 | pmid=23051717 | doi=10.1016/S0140-6736(12)60680-1 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23051717 }} </ref> | ||
==Prognosis== | ==Prognosis== | ||
Revision as of 02:51, 2 June 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Polymyalgia Rheumatica Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polymyalgia rheumatica natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Polymyalgia rheumatica natural history, complications and prognosis |
|
FDA on Polymyalgia rheumatica natural history, complications and prognosis |
|
CDC on Polymyalgia rheumatica natural history, complications and prognosis |
|
Polymyalgia rheumatica natural history, complications and prognosis in the news |
|
Blogs on Polymyalgia rheumatica natural history, complications and prognosis |
Overview
Polymyalgia rheumatica (PMR) affects the quality of life of the patients. The pain and stiffness in the proximal joints might lead to sleep disturbance as well as inability to do regular daily activities such as getting dressed and getting out of a chair. The symptoms begin rapidly and last for weeks. Once the steroid treatment of PMR is initiated, the symptoms resolve rapidly within few days. In fact, the rapid resolution of symptoms with the steroid therapy reinforces the diagnosis of PMR. The steroid treatment can be associated with complicationssuch as weight gain and bone fracture.[1] Approximately 40 to 50% of subjects experience relapse of the symptoms. PMR is associated with giant cell arteritis.
Natural History
- If left untreated, PMR affects the quality of life of the patients. The pain and stiffness in the proximal joints might lead to sleep disturbance as well as inability to do regular daily activities such as getting dressed and getting out of a chair. The symptoms begin rapidly and last for weeks.
Complications
- PMR is associated with giant cell arteritis. While 40 to 60% of patients with giant cell arteritis have PMR, 16 to 21% of patients with PMR develop giant cell arteritis.[2][3][4] Some symptoms of temporal arteritis include severe headaches, scalp tenderness, jaw claudication, fever, distorted vision or aching in the limbs caused by decreased blood flow, and fatigue. Giant cell arteritis is a serious condition that might lead to blindness among other complications and it must be treated with high dose corticosteroids.
- The mainstay of the treatment of PMR is low dose corticosteroids, which is byitself associated with complications. Complications of the steroid treatment include weight gain and bone fracture.[1]
Prognosis
- Once the steroid treatment of PMR is initiated, the symptoms resolve rapidly within few days. In fact, the rapid resolution of symptoms with the steroid therapy reinforces the diagnosis of PMR. Approximately 40 to 50% of subjects experience relapse of the symptoms, which requires longer duration of glucocorticoid treatment.[1] Factors that are associated with relapse are:
- Female sex
- Initial high dose glucocorticoid therapy
- Fast tapering of the glucocorticoid therapy[1]
References
- ↑ 1.0 1.1 1.2 1.3 Kermani TA, Warrington KJ (2013). "Polymyalgia rheumatica". Lancet. 381 (9860): 63–72. doi:10.1016/S0140-6736(12)60680-1. PMID 23051717.
- ↑ Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG (1995). "The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern". Ann Intern Med. 123 (3): 192–4. PMID 7598301.
- ↑ Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG (1995). "Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991". Arthritis Rheum. 38 (3): 369–73. PMID 7880191.
- ↑ Franzén P, Sutinen S, von Knorring J (1992). "Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988". J Rheumatol. 19 (2): 273–6. PMID 1629827.